TS NexGen

TS NexGen is a South Korean biotechnology company specializing in the development of advanced Natural Killer (NK) cell therapies for oncology and infectious diseases. The company utilizes a proprietary platform for the high-purity expansion and mass production of NK cells, aiming to provide effective off-the-shelf treatments. Formerly known as H-Line, the company rebranded to TS NexGen following its strategic focus on the biopharmaceutical sector and the acquisition of TS Biotech. Its lead programs include autologous and allogeneic NK cell therapies currently undergoing clinical evaluation for various solid tumors. TS NexGen is publicly traded on the KOSDAQ exchange and continues to expand its pipeline through internal R&D and CAR-NK technology development.